StandardX has closed a £10 million seed round to build what it describes as the world’s first scalable isotope refinery. The London-based startup, founded in 2025 by two nuclear engineers, aims to solve one of the energy and healthcare sectors’ quietest yet most pressing bottlenecks: the chronic scarcity of rare isotopes — materials that are essential both for cancer diagnosis and treatment and for fuelling the next generation of fusion reactors.
The round was led by Vsquared Ventures and East X Ventures, two European deep tech funds with portfolios including Neura Robotics and Proxima Fusion. Joining the lead investors are firstminute capital, the UK Innovation and Science Seed Fund (UKI2S), Brevan Howard Macro Venture, and Geometry. The capital will be used to build out the team, secure an industrial site in London, and advance the design and construction of the first particle accelerator-based refinery system.
Production will begin with oncology isotopes, with a dual purpose: supplying hospitals with the materials that already underpin diagnostic and therapeutic procedures, while also developing isotopes for next-generation radiopharmaceuticals — some of which do not yet exist in commercial form. StandardX plans to deliver its first isotopes to a medical research partner in 2027 and reach industrial-scale production from 2029. The backdrop is stark: in May 2026, the UK met only 69.6% of its national cancer treatment target, with part of that shortfall directly attributable to isotope shortages rather than any scientific limitation.
The same accelerator-based platform is designed to scale towards other advanced applications. The most significant for the energy sector is tritium, the fuel of nuclear fusion: only around 25 kilograms exist worldwide, yet a single fusion plant consumes tens of kilograms per year to operate. StandardX has already signed agreements with fusion developers to support their tritium needs. CEO Richard Pearson and CTO Ross Allen — both with track records building startups in the nuclear space, with Pearson previously at Kyoto Fusioneering — designed the company around a clear concept: a modular, portable system that enables isotope production close to the point of use and allows output to be adjusted in line with demand.
StandardX‘s approach stands out from competitors precisely because of this flexibility. Most existing players focus on a handful of isotopes or rely on a single production method; the London refinery instead targets a shared platform capable of generating multiple types of materials. Today’s global isotope supply chain is fragmented, reliant on ageing facilities, and concentrated in just a few sites. If the roadmap holds, by the end of the decade Europe could have a domestic, resilient source of materials that currently arrive from afar and in insufficient quantities — for both medicine and the fusion reactors now edging closer to the grid.
